Regulation & Compliance

With its finances in distress, Netcapital bets its future on blockchain and a new CEO. Can a turnaround specialist navigate the crypto frontier?

FDA clears Phase IIb trial for CS1, an epigenetic drug aiming to reverse PAH damage, not just manage symptoms, signaling a major market and patient shift.

Lifestyle experts are shaping your holiday shopping. We dissect the strategy behind curated gift guides, influencer endorsements, and the media firms driving them.

A new Canada-Germany digital alliance promises AI and quantum breakthroughs. But can this pact move from policy to patients and transform Canadian health?

With a new SVP of Growth, John Henry, RestorixHealth signals an aggressive push in the booming wound care market, navigating tech shifts and regulatory hurdles.

Enterprises are shifting from AI that gives answers to AI that takes action. A new forecast reveals how autonomous agents will redefine work by 2026.

Sana Biotech’s new data shows it can edit stem cells directly in the body, a potential game-changer for blood disorders and a challenge to current therapies.

As the aging U.S. grid strains under explosive demand, industrial leaders are turning to microgrids for energy independence and financial stability.

A new investment narrative targets 'essential' sectors. A deep dive reveals a complex mix of real strategy, verifiable progress, and pure promotion.

Quantum computers will soon break today's encryption. A new security standard is here, but are automakers moving fast enough to prevent a systemic failure?

A new partnership aims to revolutionize public safety with faster, smarter security screening. But can advanced AI balance security with personal privacy?

Enterprises lose up to 9% of revenue from missed contract obligations. New AI tools are turning static legal documents into actionable intelligence.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

A breakthrough drug for a rare brain cancer sweeps prestigious international awards, offering patients a new, targeted therapy to delay aggressive treatments.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

Alerus Financial’s 5% dividend increase isn’t just a payout; it’s a story of strategic diversification and resilience in a volatile banking sector.

A government crackdown on clergy and a top businessman raises serious questions about Armenia's judicial independence, spooking investors and allies alike.

Up to 60% of disability claims are denied, leaving sick Canadians in financial ruin. We explore the insurer tactics and the fight to reclaim benefits.

A legal fight over attorney fees in the Hess-Chevron deal reveals a costly risk in M&A. Here's why healthcare execs and investors should pay attention.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.